Researchers Identified New Leukemia Drug Resistance Pathway
A study in pre-B leukemia cells reveals how cells adapt to a specific drug treatment to survive.
Updated on Oct. 2, 2026 in Cancer
Scientists have uncovered a new cellular adaptation mechanism that could help explain resistance to Galunisertib, a TGF-βRI/ALK5 inhibitor currently in Phase II clinical evaluation. This discovery was made using NALM-6 pre-B leukemia cells, offering new insights into how cancer cells reorganize their energy usage when exposed to targeted therapies.
Why it matters
Understanding how cancer cells shift their dependency toward oxidative phosphorylation during treatment provides a potential strategy to prevent therapy resistance. This research marks a step toward identifying biomarkers that could eventually help predict whether a patient's cancer may become resistant to this type of drug.
A genome-wide CRISPR-Cas9 loss-of-function screen performed on NALM-6 cells identified oxidative phosphorylation as the primary enriched Hallmark gene set following Galunisertib exposure. These findings are preliminary and await validation through individual gene perturbation and metabolic testing.
The details
Galunisertib functions by inhibiting TGF-βRI/ALK5, a signaling pathway involved in cell growth. The researchers discovered that prolonged exposure to the drug forces leukemia cells to increase their reliance on oxidative phosphorylation, an efficient energy-production process in mitochondria. The analysis identified TCF4 as a key sensitizer, while vulnerabilities in mitochondrial translation and iron-sulfur cluster biogenesis were also noted as potential resistance routes.
Timeline
October 2, 2026: Article publication date.
Health Landscape
This study contributes to the growing body of research utilizing the MitoCarta3.0 database to categorize mitochondrial functions and their roles in oncological treatment resistance. It highlights a pivot in cancer research toward understanding metabolic flexibility as a primary driver of resistance to targeted inhibitors.
This research is currently in the laboratory phase and does not change clinical care or treatment decisions for patients today. If you have questions about how laboratory-stage cancer research may eventually impact treatment options, these are topics worth discussing with your oncologist.
The takeaway
This study highlights that cancer cells can survive drug treatments by shifting how they produce energy. Patients should remain informed that such findings are preclinical steps that help scientists design more effective therapies in the future.
Further reading
For more on the latest research in this field, visit our Cancer section.
More information
Review the complete findings in the peer-reviewed research article.
Source note: This article includes information reported by Nature.
